Identification of Antibodies against HPV 16 E6/E7 Proteins in Sera of Patients with Cervical Neoplasias

利用人乳头瘤病毒（HPV）16型E6、E7融合蛋白在大肠杆菌中表达，建立了敏感、特异的ELISA方法。杆菌对97名妇女（30名浸润性宫颈癌患者，26名宫颈上皮内瘤变III（CIN III）患者和38名健康对照妇女）的血清进行了E6和E7蛋白抗体的检测。E6蛋白阳性率为27%（8/30），19%（5/26），19%（5/26）; E7蛋白阳性率为33%（10/30），8%（2/26）。平均O。D.抗E7抗体阳性率在恶性肿瘤组高于CIN组，而E6抗体阳性率在两组间无显著性差异。HPV 16 E6/E7抗体与恶性转化相关的高患病率和高吸光度值表明，检测这些抗体可能是宫颈癌相关HPV 16的有用诊断辅助手段。

We developed a sensitive and specific ELISA method using the slo-fusion proteins of uman papillomavirus(HPV)16 E6 and E7, which were expressed in E. Coli. Sera from 97 women(30 patients with invasive cervical cancers, 26 patients with cervical intraepithelial neoplasia III(CIN III)and 38 healthy control women)were tested for the presence of antibodies to E6 and E7 proteins. Eight(27%)of 30 cervical cancer sera, five(19%)of the 26 CIN sel-a and none of the 38 normal sera were reactive with E6 proteins Ten(33%)of the 30cervical cancer sera, two(8%)of the 26 CIN sera and none of the 38 normal sera were reactive with E7 protein. The mean O. D. for anti-E7 antibody in positive cases was higher in cancer patients than in CIN patients, while that for E6 did not differ between these two groups. The high prevalance rates and high absorbance value for HPV 16 E6/E7 antibodies in association with malignant transformation suggest that detection of these antibodies may be a useful diagnostic aid for cervical cancer-associated HPV 16.